Author's response to reviews

**Title:** Phase II Study of the Combination Carboplatin plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients

**Authors:**

Francesco Legge (francescolegge@libero.it)
Amelia Paglia (amelia.paglia@alice.it)
Marco D'asta (marcodasta@hotmail.com)
Gilda Fuoco (gildafuoco@gmail.com)
Giovanni Scambia (giovanni.scambia@rm.unicatt.it)
Gabriella Ferrandina (gabriella.ferrandina@libero.it)

**Version:** 2  **Date:** 31 July 2010

**Author's response to reviews:** see over
Dear Editor,

Please find enclosed the electronic version of the manuscript “Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients” by Legge F. et al., which we would like to submit for publication as Original Article in *BMC Cancer*.

In our paper we report a phase II clinical trial aimed at evaluating the antitumor activity and potential adverse effects of the combination celecoxib plus carboplatin in patients with recurrent, heavily pre-treated OC. The potential changes induced by the experimental combination on angiogenesis-related serum markers and quality of life measures have been also evaluated.

The trial registration number for the phase II study Carboplatin plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients is NCT01124435 (ClinicalTrials.gov Identifier) and is 935/03 (study ID numbers).

In consideration of the encouraging results obtained with celecoxib associated to a single agent platinating compound and the potential implications for further translational studies, we hope the manuscript will be suitable for publication in your Journal.

Best regards,

Gabriella Ferrandina.

**Corresponding author:**
Gabriella Ferrandina, MD
Gynecologic Oncology Unit,
Department of Oncology,
Catholic University
Largo A. Gemelli, 1; 86100 Campobasso, Italy
Tel.:+39 0874 312343/549; Fax +39 0874 312324